安德沙班α与四因子凝血酶原复合物在退伍军人凝血因子Xa抑制剂相关脑出血中的比较:安德沙班α增加30天血栓事件
该研究为退伍军人健康管理局2018年1月至2024年1月的全国回顾性队列,比较安德沙班α(AA,n=151)与四因子凝血酶原复合物(4F-PCC,n=513)在fXa抑制剂相关脑出血中的效果与安全性。倾向评分匹配队列纳入123例。两组90天死亡率无显著差异(30.9% vs 36.6%,p=0.35);AA组30天血栓事件显著更多(11.4% vs 2.4%,p<0.01),急性缺血性卒中在AA组更常见。作者认为选择AA时应仔细权衡血栓事件风险。
要点
- 在退伍军人fXa抑制剂相关脑出血中,AA组与4F-PCC组90天死亡率无显著差异(30.9% vs 36.6%,p=0.35)。
- AA组30天血栓事件显著高于4F-PCC组(11.4% vs 2.4%,p<0.01),急性缺血性卒中在AA组更常见。
- AA组使用阿哌沙平的比例高于4F-PCC组(87.8% vs 77.2%,p=0.03)。
- 作者认为,选择AA时应仔细权衡血栓事件风险。
适用人群与场景
- 退伍军人健康管理局中诊断为fXa抑制剂相关脑出血并接受AA或4F-PCC治疗的退伍军人。
研究设计与关键结果
- 研究类型:全国回顾性队列,数据来自退伍军人健康管理局,时间范围为2018年1月至2024年1月。
- 人群:19,015例脑出血退伍军人中,664例接受AA(n=151)或4F-PCC(n=513),其中350例与fXa抑制剂相关(AA n=129;4F-PCC n=221);倾向评分匹配队列纳入123例。
- 主要有效性终点:90天死亡率在AA组与4F-PCC组间无显著差异(30.9% vs 36.6%,p=0.35)。
- 主要安全性终点:AA组30天血栓事件(静脉血栓栓塞、肺栓塞、急性缺血性卒中、心肌梗死)显著高于4F-PCC组(11.4% vs 2.4%,p<0.01),急性缺血性卒中在AA组显著更常见。
- 基线特征:AA组使用阿哌沙平的比例高于4F-PCC组(87.8% vs 77.2%,p=0.03)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在退伍军人fXa抑制剂相关脑出血中,选择AA时应仔细权衡血栓事件风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVES: Two hemostatic agents are commonly used to reverse factor Xa (fXa) inhibitor-related intracranial hemorrhage (ICH): andexanet alfa (AA) or 4-factor prothrombin complex concentrate (4F-PCC). We sought evaluate real-world data in Veterans diagnosed with fXa inhibitor-related ICH by comparing short-term mortality and thrombotic events in patients who received AA vs. 4F-PCC.
METHODS: This was a national retrospective cohort from the Veteran Health Administration of AA or 4 F-PCC between January 2018 to January 2024.The primary effectiveness endpoint was 90-day mortality. The primary safety endpoint was 30-day thrombotic events (venous thromboembolism, pulmonary embolism, acute ischemic stroke [AIS], myocardial infarction), validated through manual chart review. Propensity score-matched data set was first created to balance AA and 4F-PCC by the significant demographic and clinical variables and then was used to analyze and compare the results using the complete data set.
RESULTS: Of 19,015 Veterans with ICH, 664 Veterans received AA (n = 151) or 4F-PCC (n = 513) and 350 Veterans received a fXa inhibitor (AA n = 129; 4F-PCC n = 221). 123 matched subjects were included in the propensity-matched cohort. The AA group was more likely to be on apixaban (AA group 87.8 % vs. 4F-PCC group 77.2 %, p = 0.03). There was no difference in 90-day mortality between groups (30.9 % vs. 36.6 %, p = 0.35). The AA group experienced significantly more 30-day thrombotic events compared to 4F-PCC (11.4 % vs. 2.4 %, p < 0.01) and AIS was significantly more common with AA.
CONCLUSION: In Veterans with fXa inhibitor-related ICH receiving AA or 4F-PCC, there was no difference in 90-day mortality. Consistent with previous literature from non-Veterans studies, 30-day thrombotic events were significantly higher in Veterans who received AA, including a significant increase in AIS. This study adds to the growing body of literature demonstrating higher thrombotic risks with AA. Selection of AA should be carefully weighed against the risk of thrombotic events.
参考来源
- Rech MA, Budde E, Evans CT, et al. Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans. Am J Emerg Med. 2025. PMID: 40700941. doi:10.1016/j.ajem.2025.07.037
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。